# Research Idea Ranking

**Generated:** 2026-03-03T03:02:37.257602
**Models:** GPT-5.2, Gemini 3.1 Pro, Grok 4.1 Fast
**Reasoning:** high

## Comparison Table

| Idea | GPT-5.2 | Gemini 3.1 Pro | Grok 4.1 Fast |
|------|------|------|------|
| The Welfare Cost of Prescription Drug Mo... | PURSUE (74) | — | PURSUE (88) |
| Physician Agency in Opioid Prescribing —... | CONSIDER (63) | — | CONSIDER (68) |
| The Long-Acting Opioid Paradox — PDMPs, ... | CONSIDER (55) | — | SKIP (55) |
| Illicit Substitution and the Welfare Par... | SKIP (50) | — | CONSIDER (62) |
| Idea 1: The Welfare Cost of Prescription... | — | PURSUE (65) | — |
| Idea 4: The Long-Acting Opioid Paradox —... | — | CONSIDER (52) | — |
| Idea 3: Illicit Substitution and the Wel... | — | SKIP (42) | — |
| Idea 2: Physician Agency in Opioid Presc... | — | SKIP (35) | — |

---

## GPT-5.2

**Tokens:** 6170

### Rankings

**#1: The Welfare Cost of Prescription Drug Monitoring Programs: A Sufficient Statistics Approach**
- **Score: 74/100**
- **Strengths:** The “object” is genuinely more ambitious than the usual PDMP reduced-form: a welfare decomposition that forces the paper to quantify *what is gained* (internalities/externalities) versus *what is lost* (pain management/foregone legitimate care). If executed credibly, it has a clean A→B→C arc (PDMP → prescribing access → mortality/substitution + consumer surplus proxies → welfare).
- **Concerns:** The hard part is not estimating the DiD—it’s credibly mapping DiD moments into welfare statistics (especially the value of lost pain treatment and the internality term). There is substantial risk the welfare exercise looks “calibrated/assumption-heavy” rather than “disciplined by quasi-experimental variation,” which top journals punish.
- **Novelty Assessment:** **Medium-high novelty.** PDMP impacts are heavily studied, but *formal sufficient-statistics welfare* for opioid prescribing regulation is much less developed and could be a real contribution if it’s not just re-labeling components of an ATE.
- **Top-Journal Potential: Medium–High.** A top field journal (AEJ:EP) is very plausible; top-5 is possible **if** the welfare object is tight (transparent sufficient statistics, sharp bounds, and a compelling “policy-optimality” deliverable rather than an illustrative back-of-envelope).
- **Identification Concerns:** State staggered adoption is vulnerable to **policy bundling and endogenous timing** (states adopt amid worsening opioid trends and alongside pain clinic laws, naloxone access, Medicaid expansion, fentanyl penetration, etc.). Mortality outcomes are especially exposed to the mid-2010s fentanyl shock, which can break parallel trends in ways that are hard to diagnose with annual state data.
- **Recommendation:** **PURSUE (conditional on: (i) a serious policy-bundling strategy—explicit controls/event-time stacking for major co-policies and pre-trend diagnostics by outcome; (ii) a credible approach to valuing “lost pain management,” ideally with tight revealed-preference bounds or external validation rather than a single calibrated number; (iii) showing strong first stages in prescribing that line up temporally with the mandate).**

---

**#2: Physician Agency in Opioid Prescribing — Hassle Costs, Patient Sorting, and the Shadow Price of Regulation**
- **Score: 63/100**
- **Strengths:** Uses very rich provider-level Part D data to open the black box of *who* changes behavior (mechanisms and heterogeneity), which is exactly what editors want beyond a headline ATE. The “shadow price of hassle/regulation” is potentially a portable concept beyond opioids (broader physician regulation/design relevance).
- **Concerns:** The “continuous dose” design (interacting treatment with baseline prescribing) is not automatically causal: high baseline prescribers may have different underlying time trends, patient case-mix drift, enforcement exposure, or contemporaneous shocks. The patient-sorting story may be hard to validate because Part D demographics are coarse and you won’t observe displaced patients (they leave the prescriber, exit Medicare, pay cash, or switch to illicit markets).
- **Novelty Assessment:** **Medium.** Physician heterogeneity in prescribing and PDMP mechanisms exist in the literature; the novelty is in making *hassle costs + agency + sorting* the central estimand and quantifying an interpretable “shadow price.”
- **Top-Journal Potential: Medium.** Strong candidate for a good field journal (JHE / AEJ:EP) if the design is unusually convincing and the sorting evidence is sharp; less likely for top-5 unless it uncovers a surprising mechanism or large unintended distributional impacts.
- **Identification Concerns:** Baseline-intensity interactions often fail because of **differential pre-trends** and mean reversion. You would need event-study-by-quantile (or interacted event studies with pre-trend tests), plus falsification outcomes (non-opioid prescribing, unaffected drug classes) and careful handling of Part D reporting thresholds/suppression.
- **Recommendation:** **CONSIDER** (best positioned as a mechanism/section that strengthens Idea 1, unless you can produce very clean sorting evidence and a defensible mapping from behavior to “shadow price”).

---

**#3: The Long-Acting Opioid Paradox — PDMPs, Formulary Switching, and the Durability-Safety Tradeoff**
- **Score: 55/100**
- **Strengths:** Feasible and cleanly measured with built-in Part D long-acting (LA) fields; it targets a *policy design* margin (composition/targeting) rather than only levels. If you can show PDMPs change LA vs SA differentially, that is actionable for improving mandate design.
- **Concerns:** On its own, this risks reading as “competent but not exciting”: a composition DiD without a broader welfare, substitution, or clinical-outcomes link. Also, LA classification in Part D is not the same as clinical appropriateness; changes could reflect insurer formularies, abuse-deterrent reformulations, or manufacturer shocks rather than PDMPs.
- **Novelty Assessment:** **Medium.** Surprisingly under-explored relative to total prescribing, but still adjacent to a very crowded PDMP literature; novelty depends on whether you can connect composition changes to meaningful downstream outcomes (dependence, OUD, overdose, hospitalizations).
- **Top-Journal Potential: Low–Medium.** More likely a solid field/journal-of-record contribution unless integrated into a bigger story (targeting efficiency, welfare, or unintended harm to chronic pain patients).
- **Identification Concerns:** Same staggered-state timing threats as the others; at physician level you gain power but not necessarily exogeneity. Also need to address Part D suppression, coding changes over time, and whether LA measures are stable across years.
- **Recommendation:** **CONSIDER** (strong as an internal mechanism test within a broader paper; weaker as a standalone top-journal play).

---

**#4: Illicit Substitution and the Welfare Paradox of Supply-Side Drug Policy**
- **Score: 50/100**
- **Strengths:** The stakes are first-order (mortality), and the substitution question is central to opioid policy debates. A clean demonstration of “Rx deaths down, fentanyl/heroin deaths up” with credible timing would be policy-salient.
- **Concerns:** This is the most crowded part of the literature, and the mid-2010s fentanyl wave creates severe identification headaches at the state×year level; many plausible confounders move exactly when PDMP mandates roll out. Without a design that isolates substitution (not just correlated trends), it risks being a re-run of known results with disputed causality.
- **Novelty Assessment:** **Low.** Substitution to heroin/fentanyl after supply restrictions is widely studied; you’d need a distinctly better design or new data to move beliefs.
- **Top-Journal Potential: Low.** A top journal would likely view staggered DiD on state mortality as too fragile here unless you introduce a sharper quasi-experiment (e.g., discontinuities in enforcement, PDMP access shocks, differential integration into EHRs, border/county designs with strong diagnostics).
- **Identification Concerns:** **Non-parallel trends** driven by fentanyl market penetration, policing, treatment capacity, and reporting changes; plus policy endogeneity (states adopt in response to rising deaths). Annual state data gives limited leverage to separate these.
- **Recommendation:** **SKIP** as currently framed (worth revisiting only if you can secure a substantially sharper design or higher-frequency/within-state variation that credibly isolates substitution).

---

### Summary

This is a coherent bundle centered on an important policy lever, but three of the four ideas lean on the same fragile state-staggered timing, so differentiation hinges on whether you build a genuinely belief-changing *object* (welfare/targeting/agency) rather than another PDMP ATE. I would pursue **Idea 1 first** (with strong conditions on welfare discipline and confounding defenses), and treat **Ideas 2 and 4** as mechanism modules that can materially strengthen the main paper.

---

## Gemini 3.1 Pro

**Tokens:** 11863

Here is my evaluation of the research proposals. As requested, I have applied a highly critical lens, grounding my assessment in the empirical realities of top-journal editorial preferences and the hard constraints of causal inference. 

While the proposal notes suggest Idea 1 is an "Econometrica paper," I strongly disagree with that assessment *as the project is currently designed*. The theoretical architecture is brilliant, but the empirical execution suffers from fatal data flaws that would lead to a desk rejection at any top-5 journal. 

### Rankings

**#1: Idea 1: The Welfare Cost of Prescription Drug Monitoring Programs: A Sufficient Statistics Approach**
- **Score**: 65/100
- **Strengths**: The theoretical framing is exceptional; mapping the sufficient statistics framework onto addiction policy to estimate the welfare cost of PDMPs is exactly the kind of "new object + mechanism chain" that top journals crave. It elevates a standard policy evaluation into a first-order welfare question.
- **Concerns**: There is a fatal measurement mismatch: Medicare Part D covers seniors and the disabled, while the illicit opioid mortality crisis is overwhelmingly concentrated in prime-age adults. You cannot populate a unified welfare formula using prescribing drops in seniors and mortality spikes in 25-year-olds.
- **Novelty Assessment**: The theoretical approach (sufficient statistics for addiction) is highly novel and exciting. However, the empirical setting (PDMPs) is one of the most saturated topics in health economics.
- **Top-Journal Potential**: High (theoretically) but Low (empirically). A top-5 journal would love the sufficient statistics approach, but as noted in the Editorial Appendix, judges treat "measurement mismatch between treated population and outcome" as underpowered-by-construction. 
- **Identification Concerns**: Medicare Part D public data starts in 2013, but key early-adopter states (KY, TN, NY, WV) passed mandates in 2012/2013. This leaves zero pre-treatment periods for the most important states, making parallel trends impossible to test and violating a hard constraint for modern staggered DiD.
- **Recommendation**: PURSUE (conditional on: replacing Part D data with all-payer claims or ARCOS data that covers prime-age adults; ensuring the data panel begins pre-2010 to capture early adopters).

**#2: Idea 4: The Long-Acting Opioid Paradox — PDMPs, Formulary Switching, and the Durability-Safety Tradeoff**
- **Score**: 52/100
- **Strengths**: Focuses on a specific, clinically relevant margin (long-acting vs. short-acting formulations) that highlights the durability-safety tradeoff of PDMPs, moving beyond a simple volume ATE.
- **Concerns**: It relies on the same flawed 2013 Part D data, missing pre-periods for early adopters. Furthermore, it reads as a competent but narrow administrative evaluation rather than a field-changing paper.
- **Novelty Assessment**: Moderate. While PDMPs are overstudied, the specific composition of LA vs. SA prescribing is a less explored and highly policy-relevant margin.
- **Top-Journal Potential**: Low. This is the modal loss described in the Appendix: "technically competent but not exciting." It estimates a standard DiD on a narrow outcome without a broader welfare implication or belief-changing mechanism.
- **Identification Concerns**: Suffers from the same left-censoring of data (starts 2013) for a policy that began rolling out in 2012/2013, making pre-trend testing impossible.
- **Recommendation**: CONSIDER (conditional on: fixing the data timeline and framing it around a broader economic theory of physician risk-aversion).

**#3: Idea 3: Illicit Substitution and the Welfare Paradox of Supply-Side Drug Policy**
- **Score**: 42/100
- **Strengths**: Addresses a first-order life-and-death question regarding the unintended consequences of supply-side drug policies.
- **Concerns**: The empirical finding that PDMPs drive substitution to heroin/fentanyl has already been extensively documented in the literature. Adding a theoretical model to an old empirical fact is not enough to carry a paper.
- **Novelty Assessment**: Very Low. The substitution effect of PDMPs is conventional wisdom at this point (e.g., Alpert et al. 2018, Mallatt 2020, Kim 2021). 
- **Top-Journal Potential**: Low. Top journals reward papers that challenge conventional wisdom or reveal new mechanisms, not papers that confirm what the field already knows using standard state-level DiD.
- **Identification Concerns**: State-level mortality DiDs are standard and CDC WONDER data is sufficient, but the lack of novelty is the primary fatal flaw here.
- **Recommendation**: SKIP.

**#4: Idea 2: Physician Agency in Opioid Prescribing — Hassle Costs, Patient Sorting, and the Shadow Price of Regulation**
- **Score**: 35/100
- **Strengths**: Attempts to open the black box of how PDMPs bind by looking at physician heterogeneity and patient sorting.
- **Concerns**: Using pre-policy prescribing levels as a continuous treatment dose is highly vulnerable to mean reversion, especially during a period of intense public scrutiny of opioids where high prescribers were naturally trending downward.
- **Novelty Assessment**: Low. Physician heterogeneity and hassle costs have already been studied in this exact context (Schnell & Currie 2018; Alpert et al. 2024).
- **Top-Journal Potential**: Low. The methodological flaws combined with a narrow focus on physician hassle costs make this uncompetitive for top general-interest journals.
- **Identification Concerns**: Severe mean reversion threat (high prescribers trending down naturally) and the same 2013 Part D data truncation issue that ruins the pre-period.
- **Recommendation**: SKIP.

### Summary

This batch features one theoretically brilliant idea (Idea 1) dragged down by fatal empirical flaws, and three derivative ideas that suffer from the same data limitations. The reliance on Medicare Part D data (starting in 2013) for a policy that began in 2012, combined with the demographic mismatch between elderly Part D beneficiaries and prime-age overdose victims, dooms the empirical strategy across the board. I recommend pursuing Idea 1 only if the data source is completely overhauled to include prime-age adults and pre-2010 baseline periods (e.g., using commercial all-payer claims or DEA ARCOS data); otherwise, the institute should pass on this batch.

---

## Grok 4.1 Fast

**Tokens:** 5651

### Rankings

**#1: The Welfare Cost of Prescription Drug Monitoring Programs: A Sufficient Statistics Approach**
- **Score**: 88/100
- **Strengths**: Pioneers a sufficient statistics welfare formula tailored to opioid regulation, bridging a clear gap between reduced-form empirics and theory in a high-stakes policy area; strong causal chain (PDMP → prescribing/mortality shifts → welfare bounds via rational/present-biased/cue-triggered benchmarks) with top-journal templates.
- **Concerns**: State-level mortality DiD may suffer from low power/noise in some years/states; welfare formula relies on strong structural assumptions (e.g., uniform internalities) that could invite critique if heterogeneity is key.
- **Novelty Assessment**: Highly novel—opioid policy lit is purely reduced-form (e.g., Buchmueller, Mallatt, Alpert); no prior welfare quantification or sufficient stats application, distinct from Mulligan (2024)'s consumer model.
- **Top-Journal Potential**: High. Fits editorial winners: first-order stakes (opioid crisis welfare), new object (addiction-specific welfare formula), mechanism chain with bounds, challenges conventional wisdom on blunt PDMPs vs. pain costs (like Allcott 2019 QJE, Finkelstein 2020 QJE).
- **Identification Concerns**: Staggered DiD credible with 7+ years pre-trends and ~36 treated units, but state-year mortality risks aggregation bias if local spillovers exist; provider prescribing aligns well but needs physician fixed effects for mobility.
- **Recommendation**: PURSUE (conditional on: robust pre-trends/event studies; sensitivity to internality calibration)

**#2: Physician Agency in Opioid Prescribing — Hassle Costs, Patient Sorting, and the Shadow Price of Regulation**
- **Score**: 68/100
- **Strengths**: Leverages rich Medicare provider data for physician-level heterogeneity and patient sorting, building cleanly on established mechanisms (Alpert 2024 hassle costs); quantifies shadow price of regulation, adding policy bite.
- **Concerns**: Continuous pre-intensity "dose" in DiD risks endogeneity if high prescribers systematically differ (e.g., patient mix); narrower than welfare analysis, reads as mechanism paper without standalone punch.
- **Novelty Assessment**: Moderately novel—heterogeneity known (Schnell-Currie 2018), hassle identified (Alpert 2024), but no prior modeling/estimation of patient sorting or shadow prices from physician responses.
- **Top-Journal Potential**: Medium. Solid mechanism decomposition (hassle → sorting → access), but "competent heterogeneity" without welfare pivot or belief-changer; best as section in broader paper, per editorial pattern of rewarding chains over standalone ATEs.
- **Identification Concerns**: Physician fixed effects help, but patient sorting could confound if beneficiaries switch providers post-PDMP; pre-trends needed per high-prescribing baseline.
- **Recommendation**: CONSIDER (as mechanism complement to Idea 1)

**#3: Illicit Substitution and the Welfare Paradox of Supply-Side Drug Policy**
- **Score**: 62/100
- **Strengths**: Tests net mortality via substitution (Rx down, illicit up?), extending Mulligan (2024) to welfare with elasticity statistic; directly addresses policy paradox in hot opioid lit.
- **Concerns**: State-year mortality DiD noisy (small counts, ICD coding issues); substitution documented (Mallatt 2020), so mainly quantifies net effect without new mechanism.
- **Novelty Assessment**: Incremental—empirical substitution established (Mallatt, Alpert), theory in Mulligan; novel only in net welfare combo, but feels like replication with mortality split.
- **Top-Journal Potential**: Medium-Low. Interesting tradeoff (legal → illicit mortality), but reduced-form ATE on familiar channel without "new object" or counterintuitive chain; risks "competent but unsurprising" per appendix.
- **Identification Concerns**: Parallel trends vulnerable if illicit markets trend differently pre-PDMP; spillovers across states weaken state-level design.
- **Recommendation**: CONSIDER (if integrated into Idea 1's substitution benchmark)

**#4: The Long-Acting Opioid Paradox — PDMPs, Formulary Switching, and the Durability-Safety Tradeoff**
- **Score**: 55/100
- **Strengths**: Exploits granular Medicare LA vs. short-acting data for prescribing composition, a plausible unstudied margin with chronic pain implications.
- **Concerns**: Extremely narrow (one ratio), no theory/welfare beyond description; risks "niche outcome" without field implications or chain.
- **Novelty Assessment**: Likely novel (no cited composition studies), but marginal—fits as robustness in broader PDMP papers.
- **Top-Journal Potential**: Low. Descriptive decomposition without stakes-changing puzzle or mechanism; editorial patterns punish narrow admin margins absent first-order welfare/tradeoff.
- **Identification Concerns**: Prescriber-level DiD fine, but LA ratio may not capture safety (e.g., if doses adjust); low power if LA share small.
- **Recommendation**: SKIP (better as appendix/robustness to Idea 1)

### Summary
This is a strong batch anchored by Idea 1, which stands out as genuinely top-journal promising due to its novel welfare toolkit and policy stakes amid the opioid crisis. Pursue Idea 1 first (potentially incorporating 2/3 as mechanisms); skip 4 as it lacks ambition. Overall quality high for policy institute, but execution must nail pre-trends and structural calibrations to avoid "competent" pitfalls.

